You just read:

Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy

News provided by

Audentes Therapeutics, Inc.

Aug 21, 2018, 08:00 ET